Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COR-003 open-label phase 3 study in endogenous Cushing's syndrome
2013-002133-37Phase 3Completed
- Sponsor
- Strongbridge Biopharma
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of levoketoconazole in Cushing's syndrome and Corticotropin adenoma (ACTHoma), sponsored by Strongbridge Biopharma. Primary endpoint: Clinical responder rate at 6 months of Maintenance Phase. Started Jun 2013; status: completed.
02
Drugs
levoketoconazole
03
Conditions
Cushing's syndromeCorticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2013-002133-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002133-37.